FL9-SA

FL9-SA (also known as FL9-68) is an engineered 9-mer peptide superagonist designed to mobilize and activate MHC class Ib-restricted regulatory CD8 T cells (CD8 Tregs). Developed by researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, FL9-SA binds to the non-classical MHC class Ib molecule Qa-1 (the murine homolog of human HLA-E). This interaction strongly activates and expands CD8 Tregs, which selectively target and eliminate activated, pathogenic CD4+ T follicular helper (Tfh) cells that upregulate Qa-1-self-peptide complexes during immune responses. In preclinical models of fully mismatched heart and kidney transplantation, vaccination with FL9-SA, either alone or in combination with an mTOR inhibitor, significantly suppresses donor-specific antibody (DSA) production, reduces graft pathology (such as C4d deposition), and prolongs allograft survival, highlighting its therapeutic potential for promoting transplant tolerance and treating autoimmune disorders.

Other names

FL9 peptide superagonistFL-9 peptide superagonistFL 9 peptide superagonistFL9 superagonistFL-9 superagonistFL 9 superagonist